Journal of Pharmaceutical Health Services Research, published by Oxford University Press, stands as a vital resource within the fields of pharmacology, toxicology, and health economics. With a focus on the integration of pharmaceutical science and healthcare services, this journal addresses the rapidly evolving challenges faced by researchers and practitioners alike, promoting innovative solutions that can enhance patient care and improve health outcomes. Its Q3 ranking in key categories such as Economics and Pharmacology further highlights its significance in the academic landscape. Although not an open-access journal, the Journal of Pharmaceutical Health Services Research provides a platform for high-quality research and comprehensive reviews, making it an essential reference for those dedicated to advancing knowledge and practice in pharmaceutical health services. With converged years from 2010 to 2024, the journal continues to contribute valuable insights that foster collaboration among academics, industry professionals, and policymakers, reinforcing its role as a cornerstone of pharmaceutical research and health service innovation.

Global & Regional Health Technology Assessment (ISSN: 2284-2403; E-ISSN: 2283-5733) is an esteemed open-access journal published by ABOUTSCIENCE SRL, dedicated to the dissemination of research in the field of health technology assessment on a global and regional scale. Since its inception in 2014, this journal has focused on the critical evaluation of health technologies, providing invaluable insights into their efficacy, cost-effectiveness, and impact on healthcare systems. With an increasing emphasis on public health and policy implications, the journal encourages interdisciplinary research that bridges gaps between technological innovations and health outcomes. Despite its relatively recent establishment, it has made significant inroads with Scopus rankings reflecting the growing importance of health technology assessment in global health discourse. The journal welcomes contributions from researchers, professionals, and students, inviting them to engage in discussions that shape the future of health technology, with the aim of informing stakeholders and policymakers worldwide.

PHARMACOECONOMICS, published by ADIS INT LTD, is a prestigious international journal dedicated to disseminating research in the fields of health policy, pharmacology, and public health. With an impressive impact factor and a solid Q1 ranking across its relevant categories, this journal plays a crucial role in shaping policy decisions, optimizing health resources, and enhancing pharmacoeconomic evaluations globally. The journal not only targets researchers and professionals but also serves as an invaluable resource for students striving to understand the economic implications of pharmaceutical care. Operating since 1992 and continuously evolving through 2024, PHARMACOECONOMICS invites contributions that address the complexities of drug expenditure, health outcomes, and public health implications, thereby fostering informed decision-making in healthcare systems. Readers can explore cutting-edge studies and analyses aimed at balancing cost-effectiveness with clinical effectiveness, making this journal a cornerstone for stakeholders invested in the future of health economics.

Gesundheitsoekonomie und Qualitaetsmanagement, published by THIEME MEDICAL PUBL INC, serves as a vital resource in the field of health policy, particularly within the context of Germany. Since its inception in 1999, this journal has been committed to advancing the discourse on health economics and quality management, making significant contributions to understanding the complexities of healthcare systems. With an impact factor that reflects its ongoing importance, the journal is categorized in the Q4 quartile for Health Policy as of 2023, indicating its role in serving a niche yet crucial space in medical literature. Although currently not an open access journal, it remains accessible through various academic platforms, making its content available to a diverse audience of researchers, healthcare professionals, and students eager to engage with contemporary issues in health economics. With its publication continuing through 2024, Gesundheitsoekonomie und Qualitaetsmanagement is essential for anyone looking to deepen their understanding of the economic aspects of healthcare and ensure quality management in health services.

Expert Review of Pharmacoeconomics & Outcomes Research is a leading journal published by TAYLOR & FRANCIS LTD, focusing on the critical intersection of pharmacoeconomics and healthcare outcomes. Established in 2001, the journal has been a key resource for researchers and professionals in the fields of health policy, medicine, and pharmacology, consistently ranked in the top quartile of these categories for its influential insights. With an ISSN of 1473-7167 and an E-ISSN of 1744-8379, it delivers cutting-edge research that informs healthcare decisions and policy frameworks. The journal's rigorous peer-review process ensures the publication of high-quality, impactful articles that address contemporary challenges and advancements in pharmacoeconomic evaluations. As of 2023, it boasts a commendable ranking of #106 in Health Policy and #124 in Pharmacology, affirming its relevance and contribution to the field. Despite being a subscription-based journal, the strength of its content makes it an invaluable tool for researchers and practitioners aiming to enhance patient outcomes and optimize resource allocation in healthcare systems.

Health Economics Review is a premier, peer-reviewed journal dedicated to advancing knowledge and research in the dynamic field of health economics and policy. Published by BMC, this Open Access journal has been a vital resource since 2011, providing a platform for scholars and practitioners to share their findings and insights on pressing health policy issues. With an impressive Q2 ranking in the Health Policy category and a Scopus rank of 113 out of 310, it reflects a solid standing within the academic community, capturing a 63rd percentile ranking that underscores its contribution to the field. The journal covers an extensive range of topics including health systems, economic evaluations, and policy analysis, making it essential reading for researchers, health professionals, and policymakers. Located in Germany, with an operational address at CAMPUS, 4 Crinan St, London, the journal is committed to fostering innovation and collaboration in health economics, thereby shaping a healthier future for all.

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE is a leading academic journal published by Cambridge University Press, specializing in the critical evaluation of healthcare technologies and their impact on health policy. Established in 1970, it has gained recognition within the field, currently holding a prestigious Q2 ranking in Health Policy, with a commendable position of #89 out of 310 in the Scopus rankings, placing it in the 71st percentile. The journal serves as an essential platform for researchers, professionals, and students interested in the intersection of technology and health care, facilitating the dissemination of innovative research findings and practical assessments that inform policy-making and improve health outcomes. With a focus on advancing knowledge from 1985 to 2024, the journal's content remains relevant and impactful. Though not open access, it offers subscription-based access to a wealth of articles that contribute to shaping the future of healthcare technology assessment.

Pharmacoeconomics-Open, an esteemed journal published by SPRINGER INT PUBL AG, is a vital resource for scholars and practitioners in the fields of health policy and pharmacology. Since its transition to an Open Access platform in 2017, the journal has aimed to democratize access to valuable research, fostering innovation and collaboration globally. With notable rankings in the 2023 Scopus indices—including Q2 in Health Policy and both categories of Pharmacology—Pharmacoeconomics-Open engages with pressing issues in health economics, providing insights into cost-effectiveness analyses and healthcare decision-making. The journal’s commitment to high-quality, peer-reviewed articles ensures that it remains a significant player in advancing knowledge and understanding within its disciplines, serving as an essential forum for researchers, policymakers, and students alike.

The Journal of Managed Care & Specialty Pharmacy is a premier publication in the realm of health policy and pharmaceutical science, dedicated to enhancing the understanding and practices surrounding managed care systems and specialty medications. Published by ACAD MANAGED CARE PHARMACY, this journal boasts an impressive Q1 ranking in both Pharmaceutical Science and Pharmacy, underscoring its significance in advancing professional discourse and research in these critical areas. With a focus on innovative care strategies and patient-centered approaches, it aims to share impactful research, reviews, and opinions that shape the future of health policy and pharmaceutical practices. The journal is available in an open access format, ensuring that vital information is universally accessible to researchers, practitioners, and policymakers alike. With its inception in 2014 and an ongoing commitment to excellence through 2024, the journal is firmly established as a leading resource within its field, making it essential reading for professionals dedicated to improving managed care and specialty pharmacy solutions.